CALCISCON develops algorithms that can predict the patient’s response to treatment, enabling personalized therapies that can successfully reduce calcification-related cardiovascular (CV) events. The algorithm relies on Calciscon T50® test, along with other routinely measured patient characteristics. The predictive algorithm allows the treating physician to prescribe the most effective drug to effectively slow down calcification. This paradigm shift in the delivery of care prevents up to half of the CV events among those patient groups most affected by vascular calcification. Calciscon is based in Switzerland, has a strong IP position, and already conducted studies in over 30,000 patients.